- Joined
- Jan 18, 2008
- Messages
- 42
- Reaction score
- 0
I've been doing research for the past several months about whether or not there's a benefit to doing pre-hospital resuscitation with hypertonic saline and dextran has benefits for hypovolemic shock patients. I was really excited when I read about the proposal by the Resuscitation Outcomes Consortium to enroll a population of about 5000 in the study-- finally (I thought naively) a straight answer with a hefty sample size.
Only, they've suspended the study due to "concerns about patient safety, relative to the likelihood of benefits." I'm wondering if anyone knows what happened.
Since the likelihood of a patient having a negative reaction to HTS or Dextran is almost zero, so I'm curious as to what safety issues they encountered. Or is it more likely the simply couldn't show any long-term benefit for HTS+D as a resuscitation fluid (which has been a problem for past studies) and called it quits early?
Only, they've suspended the study due to "concerns about patient safety, relative to the likelihood of benefits." I'm wondering if anyone knows what happened.
Since the likelihood of a patient having a negative reaction to HTS or Dextran is almost zero, so I'm curious as to what safety issues they encountered. Or is it more likely the simply couldn't show any long-term benefit for HTS+D as a resuscitation fluid (which has been a problem for past studies) and called it quits early?